CMC leader Peter is enthusiastic about adding go-getters to his team - people who are eager to contribute cross-functionally and manage external collaborators to drive ModeX’s programs from discovery to the clinic. Learn how to join the team: bit.ly/47Pb0GT #biotechjobs

Our President and CEO Gary Nabel will give the plenary address at NIH's Industry Day this Thursday, January 18. He will focus on the industry perspective on NIH research being done to target unmet needs across the U.S. Learn more: bit.ly/48X773k

Our President and CEO Gary Nabel spoke at NIH's Industry Day to discuss how public and private sectors can work together towards a shared goal of saving lives, like our partnership with BARDA to leverage our multispecific antibody platform MSTAR to combat infectious disease.

We're creating next generation therapies by uniting the power of multiple medicines into a single molecule. In #cancer, our multispecifics can expand the number of targeted tumor antigens and enable better immune system activation. bit.ly/3FOQRoe #WorldCancerDay

One of the first people ModeX employees meet is our Head of HR Lana DeAngelis who is passionate about empowering all members of our team to meaningfully contribute to our shared mission. Learn more about what sets ModeX apart: bit.ly/47Pb0GT #Biotechjobs

Did you know that the HIV virus is one of the most genetically diverse pathogens? Our multispecific HIV antibody, derived from our MSTAR platform, has the potential to potently target more HIV strains than any monospecific antibody. Learn more: bit.ly/3FOQRoe

By combining multiple antigen-binding sites into a single molecule, our multispecific antibodies are as space-efficient as they can be. Our MSTAR platform simplifies gene expression, allowing for more efficient manufacturing & gene-based antibody delivery. bit.ly/3FOQRoe

At ModeX Alicia integrates the team's many skills to progress our goal of developing transformative #multispecific medicines. Managing projects on the oncology team, she treats every day as an opportunity to advance our pipeline. More on us: bit.ly/47Pb0GT #biotechjobs

On #EmployeeAppreciationDay we thank the ModeX team who embody our commitment to creating innovative medicines with their drive for scientific excellence, mission-oriented focus and collaborative spirit. We’re endlessly proud of all the work that you do! #biotechjobs #MakingModeX

Today we announced results from a Phase 1 clinical study of SAR441236, a trispecific antibody for the treatment and prevention of #HIV, at the 2024 Conference on Retroviruses and Opportunistic Infections (#CROI). Learn more: bit.ly/4c2Jzw3

Happy International Women's Day! Today we celebrate each of the incredible women at ModeX for their commitment to advancing science and creating new medicines. We're grateful to be able to empower each other on our path to making a difference for patients together. #IWD24

On the latest #BioCenturyThisWeek podcast: Pediatric PRVs, Biosecure in Congress & @NovoNordisk’s #obesity miss, with @SteveUsdin1 Stephen Hansen 🇺🇦 @Jeff_Cranmer buff.ly/4efWVpm

Want to know more about what we do? Check out our latest publication in Science Translational Medicine, where we show the potential of multispecific antibodies against #COVID-19. Read more here: science.org/doi/10.1126/sc…

ModeX is excited to share information about MDX2001, a novel tetraspecific T cell engager for treatment of advanced solid tumors, at #SITC24 on Nov. 8. Stop by our posters in the Exhibit Hall to learn more. Details found here: bit.ly/40r06qj Tags: $OPK

#ICYMI Modex was thrilled to be presenting preclinical data on MDX2001, a tetraspecific for targeting solid tumor malignancies today at #SITC24 Details found here: bit.ly/40r06qj $OPK

Excited to share that Dr. Ronnie Wei, Head of Biologics Discovery and Development, appeared on the Nellie Podcast to answer questions on what antibodies are, how they are made, and why development in this space has accelerated rapidly. Listen here: bit.ly/41mZsul $OPK

Join Us: Jefferies Global Healthcare Conference: OPKO Health, Inc. (OPK): opko.com/investors/news…

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰 𝐍𝐢𝐠𝐡𝐭: From Boston, former NIH Director Elias Zerhouni will discuss with BiotechTV the current political and policy environment, and how it is affecting science.

Don’t miss ModeX Therapeutics’s poster presentation at #ESMO25 and stay at the forefront of research with multispecific antibodies. Learn more about our pipeline here: bit.ly/42LYd80

We are excited to announce we have initiated Phase 1/2a clinical trial (NCT07110584) with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology and immune disorders. See here for more bit.ly/436FmEW $OPK #multispecifics #antibodies